Interim report
Page 1
02 Financial Summary for the group KSEK Profit / loss before tax Total assets Earnings per share before and after dilution ( SEK ) Cash and cash equivalents as per period end Equity ratio as per period end Significant Events Significant events during the second quarter of 2021 World leading rheumatology authority Professor Costantino Pitzalis collaborates with Cyxone on Rabeximod Phase 2b study . ● ● Cyxone AB ( publ ) receives approximately SEK 18.2 million through exercised warrants of series TO4 . Cyxone appointed new COO and CFO . Interim Report Q2 2021 January - June Tara Heitner , CEO Phone : +46 ( 0 ) 70 781 88 08 E - mail : tara.heitner@cyxone.com Q2 2021 -11 458 69 240 -0,19 54 054 92,6 % Cyxone AB ( Corp. reg . no . 559020-5471 ) CYXONE Q2 2020 ● -14 197 58 357 -0,29 41 611 89,3 % Q1 - Q2 2021 -20 069 69 240 -0,34 54 054 92,6 % Significant events after the end of the period Q1 - Q2 2020 ● Cyxone and Medical University of Vienna announce collaboration to study broader T20K use in MS . Cyxone announces Rabeximod in Covid - 19 Phase 2 trial closed , data to be reported in Q3 The group was formed on 30 July 2019 when Cyxone AB formed the subsidiary Cyxone Switzerland AG . The Group's Financial reports are prepared in accordance with International Financial Reporting Standards ( IFRS ) , as adopted by the EU . The parent company applies the Swedish Annual Accounts Act ( 1995 : 1554 ) and RFR 2 Accounting for Legal Entities , as the Group applies IFRS . The interim report for the parent company has been prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act , Interim Report . Details of the Group's and parent company's accounting principles under IFRS are available on Cyxone's website : cyxone.com/investorrelations/ . This is a translation of the original Swedish version of the interim report . In case of any discrepancy between this translation and the Swedish original , the latter shall prevail . -24 394 58 357 -0,50 41 611 89,3 % This information is such information as Cyxone AB ( publ ) is obliged to make public pursuant to the Swedish Securities Markets Act . The information was submitted for publication , through the agency of the contact person set out above , at 08.30 a.m. CEST on 27 August 2021 . Interim Report Q2 2021 | 1